Schneider J, Efferth T, Centeno M M, Mattern J, Rodríguez-Escudero F J, Volm M
Department of Obstetrics and Gynaecology, Hospital de Cruces, Universidad del Pais Vasco, Baracaldo, Spain.
Eur J Cancer. 1993;29A(4):554-8. doi: 10.1016/s0959-8049(05)80150-9.
The overexpression of P-glycoprotein was studied in 10 normal endometrial controls (five from the proliferative and five from the secretory phase of the menstrual cycle) and in 23 endometrial carcinomas of different histological varieties, using the C219 and JSB-1 monoclonal antibodies. Three of the tumours had been previously treated with combination chemotherapy containing doxorubicin. All endometrial carcinomas, whether treated or untreated, as well as the normal endometrial controls from both the proliferative and the secretory phase of the menstrual cycle, overexpressed P-glycoprotein. This puts endometrial carcinoma into the same category as other tumours arising in organs which normally overexpress P-glycoprotein, all of which tend to be intrinsically resistant to chemotherapy.
使用C219和JSB-1单克隆抗体，对10例正常子宫内膜对照（月经周期增殖期5例，分泌期5例）和23例不同组织学类型的子宫内膜癌进行了P-糖蛋白过表达研究。其中3例肿瘤先前接受过含阿霉素的联合化疗。所有子宫内膜癌，无论是否接受过治疗，以及月经周期增殖期和分泌期的正常子宫内膜对照，均有P-糖蛋白过表达。这使子宫内膜癌与其他通常过表达P-糖蛋白的器官发生的肿瘤归为同一类，所有这些肿瘤往往对化疗具有内在抗性。
